PetMed Express, Inc. filings document the regulatory record for a Florida public company operating the PetMeds and PetCareRx pet pharmacy businesses. Annual and current reports disclose operating results, non-GAAP reconciliations, intangible-asset impairment matters involving the PCRX trade name, and the financial reporting issues reflected in Forms 12b-25 and Nasdaq continued-listing notices.
Other filings cover governance and capital-structure matters, including annual meeting voting results, director elections, executive compensation advisory votes, audit committee composition, amendments to the shareholder rights agreement, and modifications to security holder rights. The record also includes Form 8-K disclosures for material agreements, board appointments, results releases, and listing compliance communications.
PetMed Express CEO and President Jeffrey Allen Willard received a 250,000-share restricted stock award and 250,000 Performance Share Units (PSUs) on September 28, 2026. His reported post-grant positions were 250,000 common shares and 250,000 PSUs. The restricted shares vest one-third on each of the first three grant anniversaries, subject to continued employment, with accelerated vesting upon death, disability, a change of control, or certain terminations. Each PSU is a contingent right to one common share if predetermined levels of the company’s total shareholder return relative to the S&P 600 Specialty Retail Index are achieved over the three-year performance period ending September 27, 2029.
PetMed Express Inc. (PETS) identifies Jeffrey Allen Willard, CEO and President, as a reporting person in a Form 3 beneficial ownership filing.
PetMed Express, Inc. (PETS) amended its 2024 Inducement Incentive Plan effective September 27, 2026, increasing shares reserved for issuance by 500,000 to 850,000. The increase corresponds to 250,000 shares of restricted stock and 250,000 performance share units the company agreed to grant Jeffrey Allen Willard, its new Chief Executive Officer, on or after his September 28, 2026 start date. Other than the reserve increase, the amendment made no further changes to the plan. Awards may be made only to individuals who were not previously employees or non-employee directors, or following a bona fide period of non-employment, as an inducement material to entry into employment.
PETMED EXPRESS INC (symbol: PETS) is the issuer of record for a Form 4 filing submitted to the SEC. Elkeles Tamar reported acquisition or exercise transactions in this Form 4 filing.
PETMED EXPRESS INC (PETS) reported that director Tamar Elkeles received a grant of 49,923 shares of Common Stock on September 17, 2026. The award is a restricted stock award under the PetMed Express, Inc. 2024 Omnibus Incentive Plan, granted at $0.00 per share and held as direct ownership. The restricted shares vest in full on September 17, 2027, subject to Dr. Elkeles’ continued service on the Board of Directors. No transactions were made under a Rule 10b5-1 trading plan.
PETMED EXPRESS INC (PETS) reported the initial insider holdings of Tamar Elkeles as a director on a Form 3. The filing lists no reportable transactions, acquisitions, or dispositions of PETS securities and shows no derivative positions or post-transaction holdings, serving solely as an initial ownership disclosure.
PetMed Express, Inc. (PETS) announced that its Board of Directors appointed Tamar Elkeles, Ph.D. as an independent director effective September 17, 2026, and increased the Board size to 5 directors.
She will serve until the 2027 annual meeting or until a successor is elected and qualified. The Board determined she is an independent director under Nasdaq listing standards and the Company’s Corporate Governance Guidelines. Dr. Elkeles will serve as Chair of the Compensation and Human Capital Committee and as a member of the Corporate Governance and Nominating Committee, receiving compensation under the existing Non-Employee Director Compensation Program and an indemnification agreement consistent with other directors. The company also issued a press release on September 21, 2026 describing her appointment and background.
PETMED EXPRESS INC (PETS) announced a leadership transition, appointing Jeffrey Allen Willard as Chief Executive Officer, President, and director effective September 28, 2026, succeeding Leslie C.G. Campbell, who has served as Interim CEO and President since August 2025 and is retiring from the Board.
Mr. Willard’s Executive Employment Agreement has an initial three-year term, an initial annual base salary of $550,000, a $120,000 signing bonus (subject to repayment under certain early-departure scenarios), and a $50,000 relocation allowance (repayable on a sliding scale if he departs within two years). He is eligible for an annual performance bonus with a target of 75% of base salary and a maximum of 150% of base salary, with the fiscal 2027 bonus prorated.
Equity incentives include an initial grant of 250,000 shares of restricted stock vesting in three annual tranches and up to 250,000 performance stock units tied to three-year total shareholder return relative to the S&P 600 Specialty Retail Index, plus ongoing annual long-term incentive awards targeted at $750,000 (half restricted stock, half PSUs) capped at the lesser of that dollar value or 1.0% of outstanding common shares per grant. If terminated without Cause or resigning for Good Reason, he may receive up to 12 months of salary and COBRA reimbursement, increasing to 24 months of salary and 18 months of COBRA reimbursement if such termination occurs within 12 months after a Change of Control. If a Change of Control occurs before the 24‑month anniversary of his start date, all unvested equity is forfeited and he instead may receive a one-time $1,500,000 cash transaction bonus if per-share consideration is at least $4.00. Justin Mennen, an existing independent director, will become Chair of the Board effective September 28, 2026, and the Lead Independent Director role will be eliminated.
Campbell Leslie C.G. reported acquisition or exercise transactions in this Form 4 filing.
PETMED EXPRESS INC reported that Interim CEO and President Leslie C.G. Campbell received a grant of 60,000 shares of Common Stock as a restricted stock award under the PetMed Express, Inc. 2024 Omnibus Incentive Plan on 2026-08-11. The award vests in full on the first anniversary of the grant date, subject to continued employment and possible accelerated vesting upon death, disability, a change of control, or certain terminations of employment. Following this grant, Campbell directly holds 145,000 shares of Common Stock. An additional 30,000 shares are held in the Leslie C.G. Campbell 2020 Irrevocable Trust for family members; Campbell is not a beneficiary and disclaims beneficial ownership of those trust shares.
PetMed Express, Inc. reported for the quarter ended June 30, 2026 net sales of $41.0 million, down 19.9% from a year earlier, driven mainly by lower prescription medication sales and reduced marketing spend. Gross margin slipped to 27.6%, and the company posted a net loss of $6.1 million, or $(0.28) per share, versus a prior-year loss of $34.2 million that included large impairment charges. Adjusted EBITDA was a loss of $3.4 million. Cash and cash equivalents declined to $13.1 million, with a working capital deficit as current liabilities exceeded current assets by about $13.0 million. Management identified conditions that initially raised substantial doubt about continuing as a going concern but concluded this doubt is alleviated based on planned cost and capex reductions. Subsequent to quarter-end, the company agreed to a $37.0 million sale-leaseback of its Delray Beach headquarters and distribution center and is reviewing a public, unsolicited, non-binding cash acquisition proposal at $3.00 per share from SilverCape Investments Limited.
Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation report beneficial ownership of common stock of PETMED EXPRESS INC. The filing states that they collectively beneficially own 1,131,230 shares of common stock, representing 5.29% of the outstanding class as of June 30, 2026.
The reporting persons have sole voting power and sole dispositive power over all 1,131,230 shares, with no shared voting or dispositive power. Certain funds managed by Renaissance Technologies LLC have the right to receive dividends and proceeds from the sale of these securities.